Lepu Medical Technology (Beijing) Co., Ltd. (SHE: 300003) announced that its majority‑owned subsidiary Shanghai Minwei Biotechnology Co., Ltd. (“Minwei Bio”) has received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) (IND No.: 182860) for MWN117 Injection, a first‑in‑class INHBE‑targeting siRNA drug for the treatment of overweight or obesity – marking the first time a gene‑silencing therapeutic targeting the Activin E fat‑storage pathway has advanced to human clinical trials.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | FDA (United States) |
| Application Type | Investigational New Drug (IND) – Study May Proceed |
| IND Number | 182860 |
| Product | MWN117 Injection (siRNA) |
| Indication | Overweight or obesity |
| Sponsor | Shanghai Minwei Biotechnology Co., Ltd. (subsidiary of Lepu Medical) |
| Trial Design | Phase I, randomized, double‑blind, placebo‑controlled, single ascending dose (SAD) in healthy overweight/obese subjects (subcutaneous injection) |
| Prior Regulatory Approval | China CDE clinical trial approval (August 2026), same indication |
| Intellectual Property | Global IP rights held by Minwei Bio |
| Competitive Status | No similar drug approved globally (INHBE‑targeting siRNA) |
Drug Profile & Mechanism of Action
- Molecule: MWN117 – an siRNA (small interfering RNA) drug independently developed by Minwei Bio with global intellectual property rights
- Target: INHBE (Inhibin Subunit Beta E) – a member of the TGF‑β superfamily that is specifically expressed in hepatocytes (liver cells)
- Mechanism – The Activin E Fat‑Storage Pathway:
- INHBE protein dimerizes to form Activin E, which is released by the liver into systemic circulation
- Activin E travels to adipose tissue and binds the ALK7 receptor on adipocyte surfaces
- ALK7 activation triggers downstream Smad2/3 signaling, which inhibits lipolysis (fat breakdown), promotes lipid storage, and induces insulin resistance
- MWN117 silences the INHBE gene via RNA interference (RNAi), reducing Activin E production and thereby de‑activating the Activin E–ALK7 fat‑storage pathway, leading to effective reduction of lipid accumulation
- Innovation: First‑in‑class gene‑silencing therapeutic for obesity that targets the hepatic–adipose signaling axis, representing a fundamentally novel mechanism distinct from GLP‑1 receptor agonists, lipase inhibitors, and all currently marketed anti‑obesity drugs
- Dosing Advantage: Non‑clinical data demonstrated pharmacodynamic effects lasting ≥12 weeks after a single injection, suggesting potential for quarterly or less frequent dosing – a meaningful convenience advantage over daily or weekly GLP‑1 therapies
Preclinical Evidence – Non‑Human Primate Pharmacodynamics
| Endpoint | MWN117 Monotherapy | MWN117 + GLP‑1 RA Combination |
|---|---|---|
| Body Fat Percentage | Significant reduction | Synergistic reduction (exceeds GLP‑1 RA alone) |
| Visceral Fat | Significant reduction | Synergistic reduction (exceeds GLP‑1 RA alone) |
| Body Weight | Significant reduction | Synergistic reduction – weight loss significantly exceeds GLP‑1 RA monotherapy |
| Muscle Mass | Increased (muscle‑sparing effect) | Significantly preserves muscle – suppresses GLP‑1 RA‑associated muscle loss |
| Duration of Effect | Single injection effect sustained ≥12 weeks | – |
| Safety | Good safety profile in safety evaluation studies | – |
The spontaneously obese rhesus monkey model – widely regarded as the most translationally relevant preclinical model for obesity pharmacotherapy – demonstrated that MWN117 delivers a dual therapeutic benefit of fat loss and muscle gain when used alone, and a synergistic enhancement when combined with GLP‑1 receptor agonists. Critically, MWN117 significantly suppressed the muscle wasting that is a well‑documented side effect of GLP‑1 RA monotherapy, addressing one of the most clinically significant limitations of current incretin‑based obesity therapies.
Clinical Context – Obesity Treatment Landscape
| Current Therapy | Mechanism | Key Limitation |
|---|---|---|
| GLP‑1 RAs (semaglutide, tirzepatide) | Incretin receptor agonism – appetite suppression, slowed gastric emptying | Muscle loss (up to 30–40% of weight lost is lean mass); weekly injection; GI side effects |
| Orlistat | Lipase inhibitor | Modest efficacy; GI intolerance |
| Bariatric surgery | Surgical restriction/malabsorption | Invasive; limited access; irreversible |
| MWN117 (INHBE siRNA) | Gene‑silencing of hepatic fat‑storage signaling – promotes lipolysis, reduces lipid storage | Phase I; human data pending |
The global obesity therapeutics market is dominated by GLP‑1 receptor agonists, which have transformed the treatment landscape but carry a well‑characterized risk of lean mass (muscle) loss alongside fat loss. MWN117’s demonstrated ability to preserve or increase muscle mass while reducing fat – and to synergistically enhance GLP‑1 RA efficacy while counteracting GLP‑1‑associated muscle wasting – positions it as a potentially transformative combination partner for the next generation of obesity treatment regimens.
Market Impact & Outlook
- Obesity Market Scale: The global anti‑obesity drug market is projected to exceed US$100 billion by 2030, driven by the explosive growth of GLP‑1 receptor agonists. A novel siRNA therapeutic with a differentiated mechanism and quarterly or less frequent dosing could capture meaningful share in a market that rewards convenience and efficacy.
- GLP‑1 Combination Opportunity: MWN117’s preclinical demonstration of synergistic weight loss and muscle preservation when combined with GLP‑1 RAs positions it as a potential add‑on therapy to the existing GLP‑1 franchise – a combination strategy that could address the muscle‑loss criticism of current GLP‑1 monotherapies and unlock incremental commercial value.
- First‑in‑Class Advantage: As the first INHBE‑targeting siRNA to enter human clinical trials globally, MWN117 holds a significant first‑mover advantage in a novel therapeutic target class. No competing INHBE‑silencing drugs are known to be in clinical development.
- RNAi Platform Validation: The advancement of MWN117 into FDA‑cleared clinical trials validates Minwei Bio’s siRNA drug development platform and Lepu Medical’s strategic expansion from medical devices into innovative biopharmaceuticals.
- Dual Regulatory Footprint: Simultaneous IND clearances from both China CDE (August 2026) and U.S. FDA (October 2026) enable parallel clinical development in the world’s two largest pharmaceutical markets, maximizing development efficiency and commercial optionality.
- Lepu Medical’s Strategic Transformation: This IND milestone advances Lepu Medical’s evolution from a medical device company into a diversified medtech‑biopharma hybrid, with Minwei Bio’s siRNA platform representing a potentially high‑value biopharmaceutical growth engine.
- Next Steps: Phase I SAD trial initiation timeline, dose‑escalation results, and partnership or licensing plans Not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, regulatory trajectory, and commercial potential of MWN117 Injection in overweight and obesity. FDA IND clearance authorizes clinical trial initiation but does not indicate efficacy or predict regulatory outcomes. Actual results may differ due to risks including clinical trial performance, safety findings in humans, regulatory decisions, competitive dynamics, and the inherent uncertainties of translating preclinical RNAi data into approved therapeutics.-Fineline Info & Tech
